Company: KROS
Filing Date: 2025-08-20
Form Type: 8-K
Source: 0001664710-25-000073
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-20
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On August 20, 2025, Keros Therapeutics, Inc. (the “ Company”) issued a press release announcing that the U. S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.